Abstract
Introduction
Psoriasis is one of the most common immune-mediated skin disorders with an estimated prevalence of 2%-4% in the adult population. [1] Hyperproliferation of keratinocyte is the pathological hallmark of the disease. Psoriasis is known to be associated with an increased risk of several comorbidities including inflammatory arthritis, metabolic syndrome, and atherosclerotic disease. [2] [3] [4] The etiology of this autoimmune disorder is unknown but is believed to be an interplay between genetic predisposition and environmental factors such as smoking, high body mass index, and excessive alcohol consumption. [5] [6] [7] The association between psoriasis and enteropathy has been recognized since 1971 when Marks and Shuster [8] reported a small group of patients with severe psoriasis who presented with diarrhea/steatorrhea and were ultimately found to have enteropathy that was characterized by histological changes similar to celiac disease (CD). However, subsequent epidemiologic studies attempting to characterize this association have yielded inconclusive results, primarily because of small sample size. [9] [10] [11] [12] Therefore, to further investigate this possible relationship, we conducted a systematic review and meta-analysis of epidemiologic studies that compared the risk of CD in patients with psoriasis versus nonpsoriasis participants.
Methods

Search strategy
The first two investigators independently searched published articles indexed in MEDLINE and EMBASE database from inception to March 2016 using the search strategy that comprised the terms for psoriasis and CD as described in Supplementary Data 1. References of included studies and selected review articles were also manually searched.
Inclusion criteria
The eligibility criteria included the following: (1) Cohort study, cross-sectional study, or case-control study reporting risk of CD among patients with psoriasis compared with participants without psoriasis; (2) relative risk, hazard ratio, incidence ratio (IR), or standardized IR with 95% confidence intervals (CIs) or sufficient data to calculate those ratios were provided.
Study eligibility was independently assessed by the two aforementioned investigators. The search and literature review process were overseen by the senior investigator who resolved any different decisions between the first two investigators. Newcastle-Ottawa quality assessment scale was used to evaluate the quality of the included studies. [13] This scale assessed each study in three domains including the recruitment of cases and comparators, the comparability between the cohorts and the ascertainment of the outcomes of interest for a cohort study, and the ascertainment of exposure of interest for case-control study.
Data extraction
A standardized data collection form was used to extract the following information: First author's name, title of the study, year of publication, year of study, country of origin, study design, study population, method used to identify cases and comparators, method used to diagnose psoriasis and CD, number of participants, and demographic data of participants and confounders that were adjusted and adjusted effect estimates with 95% CI.
This data extraction was independently performed by all investigators. Any discrepancy was resolved by referring back to the original articles.
Statistical analysis
Data analysis was performed using Review Manager 5.3 software from the Cochrane Collaboration (London, United Kingdom). We pooled the point estimates from each study using the generic inverse-variance method of DerSimonian and Laird which assigned a weight for each study based on its variance. [14] In light of the high likelihood of between-study variance, we used a random effect model rather than a fixed effect model. Cochran's Q test, which is complemented with the I 2 statistic, was used to assess statistical heterogeneity. This I 2 statistic quantifies the proportion of total variation across studies that is due to heterogeneity rather than chance. A value of I 2 of 0%-25% represents insignificant heterogeneity, >25% but ≤50% low heterogeneity, >50% but ≤75% moderate heterogeneity, and >75% high heterogeneity. [15] 
Results
Our search strategy yielded 572 potentially relevant articles (428 articles from EMBASE and 144 articles from MEDLINE). After exclusion of 139 duplicated articles, 433 articles underwent title and abstract review. Four hundred and two articles were excluded at this stage since they were not observational studies, did not report the outcome of interest, or were not conducted in patients with psoriasis, leaving 31 articles for full-length article review. Twelve articles were excluded since they did not report the outcome of interest. Ten studies were excluded as they were descriptive studies without comparators, whereas five of them were excluded since they compared the prevalence of CD-related antibodies between those with and without psoriasis but did not compare the prevalence of clinical disease. Four retrospective cohort studies with 12,912 cases of psoriasis and 24,739 comparators met our inclusion criteria and were included in this meta-analysis. [9] [10] [11] [12] Figure 1 outlines our study identification and literature review process. The clinical characteristics and Newcastle-Ottawa scales of the studies included in this meta-analysis are described in Table 1 . It should be noted that the inter-rater agreement for the quality assessment was high with the kappa statistics of 0.66.
All included studies revealed an increased risk of CD among patients with psoriasis even though did not always reach the statistical significance. The pooled analysis demonstrated a significantly higher risk of CD among patients with psoriasis compared with participants without psoriasis with the pooled odds ratio of 3.09 (95% CI, 1.92-4.97). The statistical heterogeneity was insignificant with an I 2 of 0%. The forest plot of this meta-analysis is shown in Figure 2 .
To confirm the robustness of our analysis, we performed Jackknife sensitivity analysis by excluding one study at a time from the pooled analysis. The results of this sensitivity analysis ranged from 2.87 to 8.90 and remained statistically significant.
Evaluation for publication bias
Since only four studies were included in this meta-analysis, evaluation for publication bias was not performed.
Discussion
This study is the first systematic review and meta-analysis to investigate the risk of CD among patients with psoriasis using comprehensive data from all available studies. We were able to demonstrate a statistically significant increased risk of incident atrial fibrillation among patients with psoriasis with approximately 3-fold increased risk of CD compared with participants without psoriasis.
The pathophysiologic mechanisms behind this increased risk are not known, and further investigations are required. However, there are few possible explanations.
First, the association between CD and several autoimmune diseases, such as type I diabetes mellitus and autoimmune thyroid disease, is well documented. [16, 17] It is believed that shared genes (at-risk human leukocyte antigen [HLA] haplotypes) might be responsible for this association. For example, type I diabetes mellitus and CD share multiple common genetic loci such as HLA-DR3, HLA-DQ2, and HLA-DQ8. [18] The shared genes might play a similar role in the association between psoriasis and CD.
Second, the hyperproliferated keratinocytes found in patients with psoriasis are known to produce an excessive amount of interleukin (IL)-1 and IL-18, the essential signals for the induction of Th1 response. Interestingly, mucosal inflammation in patients with CD is also caused by activation of Th1 in response to dietary gluten. [9] Therefore, it is possible that those ILs might predispose patients to CD. Third, it is also possible that, in fact, CD increases the risk of psoriasis, but diagnosis of CD is often delayed or missed as its clinical manifestation could be subtle and nonspecific. Intestinal barrier dysfunction associated with undiagnosed or untreated CD may allow increased passage of immune triggers resulting in increased risk of autoimmune diseases including psoriasis. [10, 19] Our findings may also have implication on the management of psoriasis. Given the possible mechanistic links between the two diseases, gluten-free diet, the Birkenfeld et al. [10] Montesu et al. [11] De Bastiani et al. cornerstone for the management of CD, may also have a role in the management of psoriasis. In fact, benefit of gluten-free diet among patients with psoriasis has been observed in nonrandomized studies. [20] The major strength of this study was the advantage of systemic review and meta-analysis that comprehensively combined all available data. All of the included studies were of high quality as reflected in high Newcastle-Ottawa scores. Nevertheless, we acknowledge that the study has some limitations and the results should be interpreted with caution.
First, most of the included studies reported an unadjusted estimated effect. Therefore, confounders could play a role in this apparent association. Second, we could not perform an evaluation for publication bias as only four studies were included in the analysis. Therefore, we cannot exclude the possibility of publication bias in favor of positive studies. Third, the primary studies were conducted in only two countries which might limit the generalizability of our results to other populations.
Conclusions
Our meta-analysis demonstrated an approximately 3-fold increased risk of CD among patients with psoriasis. Whether routine screening for CD is suggested in clinical practice requires further investigations.
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What is new?
Patients with psoriasis are at approximately 3-fold increased risk of celiac disease compared with participants without psoriasis.
